On the other hand, PUFAs prevent the liver from steatosis on a basis of SREBP-1c and lipogenic gene (e.g., FAS, ACC, and SCD-1) downregulation [68] and then alleviate the hepatic inflammation by an amelioration of oxidative stress [69, 70]. The gene discussed is SCD; the disease is steatosis.